• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

    14.29 +0.04 (+0.32%)
    Streaming Delayed Price Updated: 12:06 PM EDT, Jun 24, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Summit Therapeutics Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    18 19 Next >
    News headline image
    Summit Therapeutics Announces Proposed Public Offering of Common Stock
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference
    From Summit Therapeutics
    Via Business Wire
    News headline image
    This Emerging Risk Is Unlike Anything the Biotech Industry Has Ever Experienced ↗
    Biotech companies have always licensed programs, but never so many from one region in particular. 
    Via The Motley Fool
    News headline image
    Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
    From Summit Therapeutics
    Via Business Wire
    Summit Therapeutics (NASDAQ:SMMT) Reports Widening Q4 Losses Amid Aggressive Clinical Push ↗
    Via Chartmill
    News headline image
    Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026
    From Summit Therapeutics
    Via Business Wire
    News headline image
    What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge ↗
    This biotech firm develops therapies for urothelial cancers, leveraging proprietary delivery technology and a growing clinical pipeline. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally ↗
    Vir Biotechnology develops immunology-based therapies targeting infectious diseases through global partnerships and scientific innovation. 
    Via The Motley Fool
    News headline image
    A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology
    From USA News Group
    Via GlobeNewswire
    What's going on in today's session ↗
    Via Chartmill
    Which stocks are moving on Friday? ↗
    Via Chartmill
    News headline image
    Summit Therapeutics Stock Dips After Q1 Financial Report ↗
    Summit Therapeutics Inc (NASDAQ:SMMT) shares are plummeting after reporting its first‑quarter financial results. Here's what you should know. 
    Via Benzinga
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Via Chartmill
    Stay updated with the stocks that are on the move in today's pre-market session. ↗
    Via Chartmill
    Get insights into the top gainers and losers of Thursday's after-hours session. ↗
    Via Chartmill
    News headline image
    Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now ↗
    The next 10 months might be challenging for this biotech. 
    Via The Motley Fool
    News headline image
    Summit Therapeutics to Present at Upcoming Investor Conferences
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Summit (SMMT) Q4 2025 Earnings Call Transcript ↗
    Summit (SMMT) Q4 2025 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026
    From Summit Therapeutics
    Via Business Wire
    News headline image
    One Fund Discloses $9 Million Ethereum ETF Exit as Crypto Market Downturn Worsens ↗
    The iShares Ethereum Trust ETF provides regulated exposure to ether’s price performance for institutional and retail investors alike. 
    Via The Motley Fool
    Topics ETFs Regulatory Compliance
    News headline image
    Is SharpLink Gaming Stock a Buy or Sell After Apeiron Capital Sold Its Stake Valued at $23 Million? ↗
    SharpLink Gaming connects sports fans and publishers to betting operators through affiliate marketing and data-driven acquisition solutions. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    2 Stocks That Could Soar This Year ↗
    These innovative biotechs could have plenty of upside ahead. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Summit Therapeutics
    Via Business Wire
    News headline image
    Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy
    From Summit Therapeutics
    Via Business Wire
    News headline image
    The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market
    The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year... 
    Via MarketMinute
    Topics Artificial Intelligence ETFs Initial Public Offering
    News headline image
    2 Biotech Stocks That Could Soar This Year ↗
    And, if all goes well, over the next five years as well. 
    Via The Motley Fool
    News headline image
    Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC)
    From Summit Therapeutics
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    18 19 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.